News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Response Genetics, Inc. to Offer Enhanced ALK Testing Program for Metastatic Lung Cancer Patients


6/28/2012 9:42:53 AM

LOS ANGELES--(BUSINESS WIRE)--Response Genetics, Inc. (NASDAQ:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced a new anaplastic lymphoma kinase (ALK) testing program aimed to provide clinicians a more complete picture of the ALK rearrangement status of their non-small-cell lung cancer (NSCLC) patients. The company will include its PCR-based EML4-ALK test results for patients testing negative for the ALK Break Apart fluorescence in situ hybridization (FISH) test at minimal cost.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES